Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?

Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?

Da: GRACEcast
0 0 5 anni fa
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.

Seguici su Facebook